{"nctId":"NCT01188811","briefTitle":"Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)","startDateStruct":{"date":"2010-10"},"conditions":["Multiple Sclerosis, Chronic Progressive"],"count":54,"armGroups":[{"label":"Arm 1: lipoic acid","type":"EXPERIMENTAL","interventionNames":["Drug: lipoic acid"]},{"label":"Arm 2: placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"lipoic acid","otherNames":["alpha lipoic acid"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of SPMS\n* Age 40-70 years\n* Able to understand English and able to give informed consent\n\nExclusion Criteria:\n\n* Unable to undergo MRI testing\n* For ambulatory subjects only, a self-reported medical or neurological condition other than MS that is a cause of progressive or fluctuating problems that affect walking(e.g. worsening neuropathy, uncontrolled lower extremity arthritis, uncontrolled heart or lung disease)\n* For ambulatory subjects only, fixed and/or stable conditions of less than 1 years duration that affect walking (e.g. joint replacement, lumbar stenosis, alcoholism, stroke, etc.)\n* Pregnant or breast-feeding.\n* Current major disease or disorder other than MS (such as cancer, kidney, heart or lung disease, post-traumatic stress disorder) that may interfere with study procedures\n* Natalizumab, mitoxantrone, azathioprine taken in the last 12 months\n* Other immunosuppressants or chemotherapies taken in the last 12 months\n* Scheduled (every 3 months or more frequently) IV steroids used in the last 12 months\n* IV or oral steroids taken in the past 60 days.\n* Lipoic acid taken in the past 60 days.\n* Subject has insulin-dependent diabetes or is not controlled on oral diabetes medications","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Brain Atrophy by MRI","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.7"},{"groupId":"OG001","value":"-1.3","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Disability Measures: Mobility","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"2.8"},{"groupId":"OG001","value":"0.1","spread":"2.0"}]}]}]},{"type":"SECONDARY","title":"Safety Measure: Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":28},"commonTop":["Fall","Urinary Tract Infection","Flu-like symptoms","Nausea","Diarrhea"]}}}